Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Aptevo Therapeutics stock
Learn how to easily invest in Aptevo Therapeutics stock.
Aptevo Therapeutics Inc is a biotechnology business based in the US. Aptevo Therapeutics shares (APVO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptevo Therapeutics employs 54 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Aptevo Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – APVO – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Aptevo Therapeutics stock price (NASDAQ: APVO)Use our graph to track the performance of APVO stocks over time.
Aptevo Therapeutics shares at a glance
|Latest market close||$3.58|
|52-week range||$3.03 - $22.50|
|50-day moving average||$4.31|
|200-day moving average||$7.96|
|Wall St. target price||$28.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-6.00|
Buy Aptevo Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Aptevo Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aptevo Therapeutics price performance over time
|1 week (2022-06-27)||-1.92%|
|1 month (2022-06-02)||-24.15%|
|3 months (2022-04-01)||-43.17%|
|6 months (2022-01-04)||-54.63%|
|1 year (2021-07-02)||-83.29%|
|2 years (2020-07-02)||-61.00%|
|3 years (2019-07-03)||325.33%|
|5 years (2017-07-03)||74.63%|
Aptevo Therapeutics financials
|Revenue TTM||$13 million|
|Gross profit TTM||$12.3 million|
|Return on assets TTM||-22.08%|
|Return on equity TTM||-1281.95%|
|Market capitalisation||$17.9 million|
TTM: trailing 12 months
Aptevo Therapeutics share dividends
We're not expecting Aptevo Therapeutics to pay a dividend over the next 12 months.
Have Aptevo Therapeutics's shares ever split?
Aptevo Therapeutics's shares were split on a 1:14 basis on 26 March 2020. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptevo Therapeutics shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Aptevo Therapeutics shares which in turn could have impacted Aptevo Therapeutics's share price.
Aptevo Therapeutics share price volatility
Over the last 12 months, Aptevo Therapeutics's shares have ranged in value from as little as $3.03 up to $22.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptevo Therapeutics's is 6.3367. This would suggest that Aptevo Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aptevo Therapeutics overview
Aptevo Therapeutics Inc. , a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG. APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.
Aptevo Therapeutics in the news
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
Frequently asked questionsWhat percentage of Aptevo Therapeutics is owned by insiders or institutions?
Currently 1.137% of Aptevo Therapeutics shares are held by insiders and 17.499% by institutions. How many people work for Aptevo Therapeutics?
Latest data suggests 54 work at Aptevo Therapeutics. When does the fiscal year end for Aptevo Therapeutics?
Aptevo Therapeutics's fiscal year ends in December. Where is Aptevo Therapeutics based?
Aptevo Therapeutics's address is: 2401 4th Avenue, Seattle, WA, United States, 98121 What is Aptevo Therapeutics's ISIN number?
Aptevo Therapeutics's international securities identification number is: US03835L2079 What is Aptevo Therapeutics's CUSIP number?
Aptevo Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03835L108
More guides on Finder
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert